Literature DB >> 25999150

Response to Ho-Wan Ip and Chi-Chiu.

N C P Cross1, M C Müller2, A Hochhaus3.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25999150     DOI： 10.1038/leu.2015.97

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Deep molecular response in chronic myelogenous leukemia: ensuring accuracy and consistency.

Authors:  H-W Ip; C-C So
Journal:  Leukemia       Date:  2015-04-24       Impact factor: 11.528

2.  Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR.

Authors:  Susan Branford; Timothy Hughes
Journal:  Methods Mol Med       Date:  2006

3.  Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Authors:  Philippe Rousselot; Aude Charbonnier; Pascale Cony-Makhoul; Philippe Agape; Franck E Nicolini; Bruno Varet; Martine Gardembas; Gabriel Etienne; Delphine Réa; Lydia Roy; Martine Escoffre-Barbe; Agnès Guerci-Bresler; Michel Tulliez; Stéphane Prost; Marc Spentchian; Jean Michel Cayuela; Josy Reiffers; Jean Claude Chomel; Ali Turhan; Joëlle Guilhot; François Guilhot; François-Xavier Mahon
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 4.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Authors:  N C P Cross; H E White; D Colomer; H Ehrencrona; L Foroni; E Gottardi; T Lange; T Lion; K Machova Polakova; S Dulucq; G Martinelli; E Oppliger Leibundgut; N Pallisgaard; G Barbany; T Sacha; R Talmaci; B Izzo; G Saglio; F Pane; M C Müller; A Hochhaus
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528
  4 in total
  1 in total

1.  Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response.

Authors:  Aliza Mohd Yacob; Nor Asiah Muhamad; Kian Meng Chang; Hamidah Akmal Hisham; Yuslina Mat Yusoff; Latifah Ibrahim
Journal:  BMC Cancer       Date:  2022-03-26       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.